Changes in viral loads of lamivudine‐resistant mutants during entecavir therapy

Aim:  Entecavir therapy is effective against lamivudine‐resistant virus in patients with hepatitis B virus infection. We investigated viral load changes of YMDD mutant virus (rtM204I [YIDD sequence], rtM204V [YVDD]) in serial serum samples during entecavir treatment for lamivudine‐resistant virus and determined changes in viral precore and core promoter mutants.

[1]  D. Moradpour,et al.  [Management of chronic hepatitis B]. , 2010, Revue medicale suisse.

[2]  Hirotoshi Nakamura,et al.  Changes in viral loads of lamivudine‐resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy , 2006, Journal of medical virology.

[3]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[4]  Yoshiyuki Suzuki,et al.  Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan , 2004, Journal of Gastroenterology.

[5]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[6]  P. Cane,et al.  Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. , 2004, Journal of hepatology.

[7]  P. Marcellin,et al.  Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy , 2004, Journal of viral hepatitis.

[8]  Yoshiyuki Suzuki,et al.  Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan , 2003, Intervirology.

[9]  Yoshiyuki Suzuki,et al.  Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study. , 2003, Journal of hepatology.

[10]  H. Conjeevaram,et al.  Management of chronic hepatitis B. , 2003, Journal of hepatology.

[11]  Yoshiyuki Suzuki,et al.  Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. , 2002, Journal of hepatology.

[12]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[13]  Yoshiyuki Suzuki,et al.  Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy , 2002, Journal of Gastroenterology.

[14]  R. J. Colonno,et al.  Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[15]  L. Corey,et al.  Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. , 2001, The Journal of infectious diseases.

[16]  M. Sherman,et al.  Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection , 2001, Hepatology.

[17]  D. Häussinger,et al.  Protein kinase C–dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells , 2001, Hepatology.

[18]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[19]  K. Hahm,et al.  Reversion from precore/core promoter mutants to wild‐type hepatitis B virus during the course of lamivudine therapy , 2000, Hepatology.

[20]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[21]  K. Tanikawa,et al.  Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. , 1999, Journal of hepatology.

[22]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[23]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.

[24]  R. D. de Man,et al.  Lamivudine resistance inimmunocompetent chronic hepatitis B , 1997 .

[25]  R. Colonno,et al.  Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus , 1997, Antimicrobial agents and chemotherapy.

[26]  R. D. de Man,et al.  Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. , 1997, Journal of hepatology.

[27]  M. Chen,et al.  Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication , 1996, Journal of virology.

[28]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[29]  S. Günther,et al.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients , 1995, Journal of virology.

[30]  U. Akarca,et al.  Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[32]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[33]  C Summers,et al.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). , 1989, Nucleic acids research.